¡Ya estamos en ! Descubre más

West Pharmaceutical

WST

Capitalización de mercado USD 27 mil M

384.02 USD

+1.00

0.26%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

384.02

0.00

0%

1 día

0.26%

5 días

4.72%

1 mes

6.08%

3 meses

5.95%

6 meses

42.33%

En lo que va del año

38.94%

1 año

43.73%

5 años

-6.04%

10 años

428.88%

Acerca de: West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Empleados: 10,800

Atención médica Instrumentos y suministros médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 67.7%

Neutral 29%

Negativo 3.2%

Zacks Investment Research

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?

West Pharmaceutical Services WST shares have gained 36.1% year to date, significantly outperforming its industry's advancement of 7.8%. The rally reflects improving demand for high-value pharmaceutical packaging components, stronger-than-expected earnings, and an upward revision to full-year guidance.

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?

Meta, JPMorgan, West Pharmaceutical And More: CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Joseph M. Terranova, senior managing director for Virtus Investment Partners, said he likes West Pharmaceutical Services, Inc. (NYSE:WST).

Meta, JPMorgan, West Pharmaceutical And More: CNBC's ‘Final Trades'

Top 50 High-Quality Dividend Growth Stocks For October 2026

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

Top 50 High-Quality Dividend Growth Stocks For October 2026

West to Host Third-Quarter 2026 Conference Call

EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 29, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.

West to Host Third-Quarter 2026 Conference Call

West Pharma: Still A Buy, But Expectations Are Rising

West Pharmaceutical Services remains a buy despite a demanding valuation, driven by new growth catalysts and robust financial performance. Double-digit growth from GLP-1s, HVP upgrades, and the multiyear Annex 1 regulatory opportunity underpin WST's bullish outlook. Annex 1 upgrades represent a multiyear, regulatory-driven mix shift, with only ~1B of a 6B component opportunity converted so far.

West Pharma: Still A Buy, But Expectations Are Rising

Best Dividend Aristocrats For October 2026

The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Dividend growth among Aristocrats in 2026 averages 4.43%, with notable increases from Nordson (14.63%) and McDonald's (3.76%) in the past month. 36 Aristocrats currently screen as potentially undervalued, each with an estimated long-term annualized return of at least 10%.

Best Dividend Aristocrats For October 2026

Zacks Investment Research

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Best Dividend Aristocrats For September 2026

Dividend Aristocrats, tracked via NOBL, delivered a 12.9% YTD return, closely trailing SPY's 13.68%, with 29 Aristocrats outperforming SPY in 2026. Top 2026 performers include TGT (+73.04%), NUE (+55.64%), and BEN (+49.25%), highlighting strong sectoral momentum among select Aristocrats. Six Aristocrats announced dividend increases in the past month, pushing the group's average 2026 dividend growth rate to 4.30%, up from 4.10% last month.

Best Dividend Aristocrats For September 2026

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™